Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Rigel Stories

2011-01-06 06:30:00

SAN FRANCISCO, Jan. 6, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the JP Morgan Healthcare Conference in San Francisco, CA on Thursday, January 13th at 11:30 a.m. PST. (Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO) To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please...

2010-12-09 06:30:00

SOUTH SAN FRANCISCO, Calif., Dec. 9, 2010 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it received the Licensing Deal of the Year award from Scrip Intelligence at the Sixth Annual Scrip Awards last month. The Award, presented jointly to Rigel and AstraZeneca, recognizes the significance of the collaboration forged by the companies to develop fostamatinib (previously referred to as R788) as a novel oral treatment for rheumatoid arthritis (RA). This is...

2010-11-23 06:30:00

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2010 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 22nd Annual Piper Jaffray Health Care Conference in New York on Wednesday, December 1st at 3:00 p.m. EST. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several...

2010-11-02 06:00:00

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2010 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30, 2010. For the third quarter of 2010, Rigel reported net income of $50.4 million, or $0.97 and $0.96 per basic and diluted share, respectively, compared to a net loss of $26.7 million, or $0.70 per basic and diluted share, in the third quarter of 2009. Basic weighted average shares...

2010-10-28 06:30:00

SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul R. Rodriguez, president and chief operating officer of Rigel, will present at two separate investor conferences in November. Details of each conference are as follows: Oppenheimer 21st Annual Healthcare Conference New York, NY November 3, 1:35 p.m. EDT Speaker: Raul R. Rodriguez...

2010-09-29 06:30:00

SOUTH SAN FRANCISCO, Calif., Sept. 29 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by...

2010-09-09 06:30:00

SOUTH SAN FRANCISCO, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Stifel Nicolaus Healthcare Conference in Boston, MA on Thursday, September 16th at 9:45a.m. EDT. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior...

2010-08-03 06:30:00

SOUTH SAN FRANCISCO, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter and six months ended June 30, 2010. For the second quarter of 2010, Rigel reported a net income of $27.0 million, or $0.52 and $0.51 per basic and diluted share, respectively, compared to a net loss of $29.9 million, or $0.81 per basic and diluted share, in the same period of 2009. Basic weighted average shares outstanding for the...

2010-07-28 06:30:00

SOUTH SAN FRANCISCO, Calif., July 28 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at BMO Capital Markets 10th Annual Focus on Healthcare Conference in New York City on Thursday, August 5th at 2:15 p.m. EDT. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website...

2010-06-03 06:30:00

SOUTH SAN FRANCISCO, Calif., June 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Ryan Maynard, executive vice president and chief financial officer of Rigel, will present at three separate investor conferences in June. Details of each conference are as follows: Jefferies Global Life Sciences Conference New York City, NY June 10, 8:00 a.m. EST Speaker: James M. Gower...